This site is updated Hourly Every Day

Trending Featured Popular Today, Right Now

Colorado's Only Reliable Source for Daily News @ Marijuana, Psychedelics & more...

Post: Psychedelic Drug Reduces Anxiety by Targeting Fast-spiking Interneurons

Picture of Anschutz Medical Campus

Anschutz Medical Campus

AnschutzMedicalCampus.com is an independent website not associated or affiliated with CU Anschutz Medical Campus, CU, or Fitzsimons innovation campus.

Recent Posts

Anschutz Medical Campus

Psychedelic Drug Reduces Anxiety by Targeting Fast-spiking Interneurons
Facebook
X
LinkedIn
WhatsApp
Telegram
Threads
Email

Summary: The psychedelic DOI, a compound similar to LSD, reduced anxiety in mice by activating specific brain cells called fast-spiking interneurons. These neurons silence nearby cells in the ventral hippocampus, a region linked to emotion and memory.

By uncovering this mechanism, the study opens the door to designing new treatments that target anxiety without triggering hallucinations, a hallmark of many psychedelics.

Key Facts : DOI activates neurons that reduce anxiety in the brain’s ventral hippocampus.

Fast-spiking interneurons silence other cells, contributing to anxiety relief.

The study suggests it’s possible to design psychedelic-inspired drugs without hallucinations.

Source: Cornell University

A classic psychedelic, similar to LSD, psilocybin and mescalin, was found to activate a cell type in the brain that silences other neighboring neurons, a result that provides insight into how such drugs reduce anxiety, according to a new study.

The findings show the psychedelic DOI (2,5-dimethoxy-4-iodoamphetamine) lessened anxiety in mice and rats while activating the ventral hippocampus and so-called fast-spiking interneurons there.

“It hasn’t been known what brain areas and cell types are involved when psychedelics suppress anxiety,” said Alex Kwan, associate professor of biomedical engineering at Cornell University and senior author of the study, which published today in the journal Neuron .“The idea is that if we know the neurobiology involved, we can design some better drug that would target these pathways.”“The work provides an understanding of the cellular trigger for the psychedelic-induced relief of anxiety,” said Vidita Vaidya, senior professor of biological sciences at the Tata Institute of Fundamental Research in Mumbai, and the paper’s corresponding author.The pathway in the ventral hippocampus – a brain structure involved in social memory, emotion and affect – does not appear to cause the hallucinations that are a hallmark of DOI, suggesting that some of the therapeutic effects of psychedelics – including reducing PTSD, depression and anxiety – may be isolated within discrete brain circuits, Vaidya said.“That opens up the possibility to design psychedelic inspired drugs that target anxiety without evoking potent hallucinations,” she added.The study builds on earlier research that identified abnormal hyperactivity in the ventral hippocampus when an animal is anxious, particularly […]

Leave a Reply

Your email address will not be published. Required fields are marked *

You Might Be Interested...